JP7515415B2 - ハンチントン病を処置するためのヘテロアリール化合物 - Google Patents
ハンチントン病を処置するためのヘテロアリール化合物 Download PDFInfo
- Publication number
- JP7515415B2 JP7515415B2 JP2020572894A JP2020572894A JP7515415B2 JP 7515415 B2 JP7515415 B2 JP 7515415B2 JP 2020572894 A JP2020572894 A JP 2020572894A JP 2020572894 A JP2020572894 A JP 2020572894A JP 7515415 B2 JP7515415 B2 JP 7515415B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- thiazolo
- fluoro
- pyridin
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024072881A JP2024105367A (ja) | 2018-06-27 | 2024-04-26 | ハンチントン病を処置するためのヘテロアリール化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690540P | 2018-06-27 | 2018-06-27 | |
| US62/690,540 | 2018-06-27 | ||
| PCT/US2019/038895 WO2020005877A1 (en) | 2018-06-27 | 2019-06-25 | Heteroaryl compounds for treating huntington's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024072881A Division JP2024105367A (ja) | 2018-06-27 | 2024-04-26 | ハンチントン病を処置するためのヘテロアリール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528466A JP2021528466A (ja) | 2021-10-21 |
| JPWO2020005877A5 JPWO2020005877A5 (enExample) | 2022-06-21 |
| JP7515415B2 true JP7515415B2 (ja) | 2024-07-12 |
Family
ID=67185796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572894A Active JP7515415B2 (ja) | 2018-06-27 | 2019-06-25 | ハンチントン病を処置するためのヘテロアリール化合物 |
| JP2024072881A Abandoned JP2024105367A (ja) | 2018-06-27 | 2024-04-26 | ハンチントン病を処置するためのヘテロアリール化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024072881A Abandoned JP2024105367A (ja) | 2018-06-27 | 2024-04-26 | ハンチントン病を処置するためのヘテロアリール化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12139499B2 (enExample) |
| EP (1) | EP3814345B8 (enExample) |
| JP (2) | JP7515415B2 (enExample) |
| KR (1) | KR20210038845A (enExample) |
| CN (1) | CN112805280B (enExample) |
| AU (2) | AU2019294482B2 (enExample) |
| BR (1) | BR112020026534A2 (enExample) |
| CA (1) | CA3104516A1 (enExample) |
| EA (1) | EA202092899A1 (enExample) |
| IL (1) | IL279714A (enExample) |
| MX (1) | MX2020014315A (enExample) |
| SG (1) | SG11202012869SA (enExample) |
| WO (1) | WO2020005877A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102488323B1 (ko) | 2015-12-10 | 2023-01-12 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| JP7376471B2 (ja) | 2017-06-05 | 2023-11-08 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
| IL272413B (en) | 2017-08-04 | 2022-09-01 | Skyhawk Therapeutics Inc | Methods and compositions for fusion modulation |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| SMT202400286T1 (it) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics Inc | Composti eterociclici ed eteroarilici per il trattamento della corea di huntington |
| AU2019294482B2 (en) | 2018-06-27 | 2022-09-01 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| JP7603592B2 (ja) | 2019-02-05 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| EP3920926A4 (en) | 2019-02-05 | 2022-10-19 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN113661162A (zh) | 2019-02-06 | 2021-11-16 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| CN114650822A (zh) | 2019-11-01 | 2022-06-21 | 诺华股份有限公司 | 剪接调节子用于减慢亨廷顿氏病进展的治疗的用途 |
| US20230322754A1 (en) * | 2020-04-28 | 2023-10-12 | Kymera Therapeutics, Inc. | Irak inhibitors and uses thereof |
| AU2021272972A1 (en) | 2020-05-13 | 2022-12-08 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| CA3183321A1 (en) | 2020-07-02 | 2022-02-06 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2022006543A1 (en) | 2020-07-02 | 2022-01-06 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| EP4308577B1 (en) * | 2021-03-17 | 2024-12-25 | F. Hoffmann-La Roche AG | New thiadiazolopyrimidone derivatives |
| CR20230437A (es) * | 2021-03-17 | 2023-10-16 | Hoffmann La Roche | Nuevos derivados de tiazolopirimidinona |
| CN116997555A (zh) * | 2021-03-17 | 2023-11-03 | 豪夫迈·罗氏有限公司 | 新颖噻吩并嘧啶酮衍生物 |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| AU2022394333A1 (en) | 2021-11-17 | 2024-06-27 | Chdi Foundation, Inc. | HTT modulators for treating Huntington’s disease |
| CN116262758B (zh) * | 2021-12-15 | 2025-02-28 | 上海博悦生物科技有限公司 | 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途 |
| AR129377A1 (es) * | 2022-05-20 | 2024-08-21 | Biogen Ma Inc | Compuestos para tratar la enfermedad de huntington |
| WO2024215070A1 (ko) * | 2023-04-11 | 2024-10-17 | 보로노이 주식회사 | 피라졸로피리딘 유도체 화합물 및 이의 용도 |
| CN121219298A (zh) * | 2023-04-20 | 2025-12-26 | 豪夫迈·罗氏有限公司 | 噻吩并[3,2-b]吡啶衍生物 |
| WO2025111408A1 (en) * | 2023-11-21 | 2025-05-30 | Biogen Ma Inc. | Compounds for treating spinal muscular atrophy and huntington's disease |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009531376A (ja) | 2006-03-28 | 2009-09-03 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | ヒスタミンｈ３受容体活性を有するベンゾチアゾール |
| WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
| WO2010024903A1 (en) | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| JP2011507884A (ja) | 2007-12-20 | 2011-03-10 | アボット・ラボラトリーズ | ベンゾチアゾールおよびベンゾオキサゾール誘導体ならびに使用方法 |
| JP2013040945A (ja) | 2011-08-18 | 2013-02-28 | Korea Institute Of Science And Technology | 退行性脳疾患の予防用または治療用の薬学的組成物及びそのスクリーニング方法 |
| WO2016144351A1 (en) | 2015-03-11 | 2016-09-15 | E. I. Du Pont De Nemours And Company | Heterocycle-substituted bicyclic azole pesticides |
| WO2017100726A1 (en) | 2015-12-10 | 2017-06-15 | Ptc Therapeutics, Inc. | Methods for treatng huntington's disease |
| WO2017175068A1 (en) | 2016-04-08 | 2017-10-12 | Mankind Pharma Ltd. | Thiazolopyridine derivatives as gpr119 agonists |
| JP2018500302A (ja) | 2014-12-02 | 2018-01-11 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての二環式化合物 |
Family Cites Families (197)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (enExample) | 1963-04-04 | 1900-01-01 | ||
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| WO1993023398A1 (en) | 1992-05-13 | 1993-11-25 | E.I. Du Pont De Nemours And Company | Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides |
| EP0698092B1 (en) | 1993-05-11 | 2007-07-25 | The University Of North Carolina At Chapel Hill | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| JPH11510478A (ja) | 1995-06-06 | 1999-09-14 | アボツト・ラボラトリーズ | キノリジノン型化合物 |
| US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| CA2269561C (en) | 1998-04-22 | 2007-06-05 | Dainippon Ink And Chemicals, Inc. | Naphthalene derivative and liquid crystal composition comprising the same |
| US6630488B1 (en) | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| EP1227084B1 (en) | 1999-10-28 | 2005-12-14 | Trine Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
| AU2001230426C1 (en) | 2000-01-24 | 2006-06-22 | Astrazeneca Ab | Therapeutic morpholino-substituted compounds |
| AU2002232536A1 (en) | 2000-11-09 | 2002-05-21 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
| US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| CA2432131C (en) | 2000-12-21 | 2008-07-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002087589A1 (en) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Medicine for inhibiting drug elimination pump |
| CA2469316A1 (en) | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| WO2004009558A2 (en) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| US7423133B2 (en) | 2002-08-23 | 2008-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent glycosides and methods for their use |
| CA2496585C (en) | 2002-09-30 | 2012-05-29 | Neurosearch A/S | Novel 1,4-diazabicycloalkane derivatives, their preparation and use |
| JP4820094B2 (ja) | 2002-11-12 | 2011-11-24 | アボット・ラボラトリーズ | ヒスタミン−３受容体リガンドとしての２環式置換アミン |
| US20070078144A1 (en) | 2003-01-29 | 2007-04-05 | Stockwell Brent R | Agents for treating neurodegenerative diseases |
| US20040224952A1 (en) | 2003-05-07 | 2004-11-11 | Cowart Marlon D. | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| EP1636225B1 (en) | 2003-06-20 | 2010-02-24 | Novartis Vaccines and Diagnostics, Inc. | Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents |
| GB0315494D0 (en) | 2003-07-02 | 2003-08-06 | Biofocus Plc | Compounds which bind to the active site of protein kinase enzymes |
| TW200517381A (en) | 2003-08-01 | 2005-06-01 | Genelabs Tech Inc | Bicyclic heteroaryl derivatives |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
| EP1697377B1 (en) | 2003-12-24 | 2011-01-26 | Biota Scientific Management Pty. Ltd. | Polycyclic agents for the treatment of respiratory syncytial virus infections |
| SE0400184D0 (sv) | 2004-01-30 | 2004-01-30 | Fyrkloevern Scandinavia Ab | New therapeutical use |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| CN1964717A (zh) | 2004-04-08 | 2007-05-16 | 神经能质公司 | 经取代∴啉－4－基胺 |
| ZA200609267B (en) | 2004-04-08 | 2009-02-25 | Targegen Inc | Benzotriazine inhibitors of kinases |
| EP1749004B1 (en) | 2004-05-04 | 2007-09-19 | Warner-Lambert Company LLC | Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents |
| WO2006078834A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP2006219453A (ja) | 2005-02-14 | 2006-08-24 | Tokyo Univ Of Pharmacy & Life Science | キノリン環を母核とする金属識別型二波長性蛍光分子 |
| US7563601B1 (en) | 2005-06-01 | 2009-07-21 | City Of Hope | Artificial riboswitch for controlling pre-mRNA splicing |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| EP1902028A2 (en) | 2005-07-04 | 2008-03-26 | Novo Nordisk A/S | Histamine h3 receptor antagonists |
| US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| US7576110B2 (en) | 2005-09-22 | 2009-08-18 | Abbott Laboratories | Benzothiazole cyclobutyl amine derivatives |
| US8258109B2 (en) | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
| US20070179123A1 (en) | 2005-11-08 | 2007-08-02 | Chiang Peter K | Methods and compositions for treating diseases associated with pathogenic proteins |
| JP2009515523A (ja) | 2005-11-10 | 2009-04-16 | サンタリス ファーマ アー／エス | Ｔｎｆスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用 |
| AU2006323986A1 (en) | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| CN101360738A (zh) | 2005-12-21 | 2009-02-04 | 佩因赛普托药物公司 | 调节门控离子通道的组合物和方法 |
| DK2161038T3 (da) | 2006-01-26 | 2014-03-03 | Isis Pharmaceuticals Inc | Sammensætninger og deres anvendelser rettet mod Huntington |
| JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| TW200812588A (en) | 2006-05-15 | 2008-03-16 | Neurogen Corp | CRF1 receptor ligands comprising heteroaryl fused bicycles |
| US7910578B2 (en) | 2006-05-23 | 2011-03-22 | Neurosearch A/S | 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use |
| WO2008011109A2 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted pyridone compounds and methods of use |
| WO2008013997A2 (en) | 2006-07-27 | 2008-01-31 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| US7994181B2 (en) | 2006-08-03 | 2011-08-09 | Rottapharm S.P.A. | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| AU2007310897A1 (en) | 2006-10-25 | 2008-05-02 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| DK2114903T3 (da) | 2006-12-22 | 2011-04-18 | Avexa Ltd | Bicykliske pyrimidinoner og anvendelser deraf |
| US20080171792A1 (en) | 2006-12-28 | 2008-07-17 | Jobdevairakkam Christopher New | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders |
| FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| EP2215074B1 (en) | 2007-09-27 | 2014-02-19 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| EP2193133B1 (en) | 2007-09-27 | 2015-08-19 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Imidazolothiadiazoles for use as protein kinase inhibitors |
| WO2009114874A2 (en) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| US20090264433A1 (en) | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
| US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| PT2315588E (pt) | 2008-06-20 | 2013-03-25 | Rottapharm Spa | Derivados de 6-1h-imidazo-quinazolina e quinolinas, novos inibidores de mao e ligandos de receptores de imidazolinas |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| CN102143962B (zh) | 2008-07-02 | 2015-03-11 | 爱维艾珂瑟有限公司 | 具有抗病毒特性的化合物 |
| US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| CA2739490A1 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| EP2396327A1 (en) | 2009-02-11 | 2011-12-21 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| FR2945289A1 (fr) | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
| CN102480966B (zh) | 2009-06-12 | 2015-09-16 | 达娜-法勃肿瘤研究所公司 | 融合的杂环化合物及其用途 |
| CA2765466A1 (en) | 2009-06-19 | 2010-12-23 | Abbott Laboratories | Diazahomoadamantane derivatives and methods of use thereof |
| RU2751847C9 (ru) | 2009-09-11 | 2021-08-20 | Ионис Фармасьютикалз, Инк. | Модуляция экспрессии гентингтина |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US20150018301A1 (en) | 2009-11-06 | 2015-01-15 | The Johns Hopkins University | LRRK-2-Mediated Neuronal Toxicity |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| BR112012017473A2 (pt) | 2010-01-13 | 2019-09-24 | Institut National De La Sante Et De La Rech Medicale Inserm Epst | pirido(1,2-a) pirimidinas, seu uso, bem como composição farmacêutica compreendendo tais compostos |
| US9006198B2 (en) | 2010-02-08 | 2015-04-14 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| WO2011097641A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Methods and compositions useful in treatment of diseases or conditions related to repeat expansion |
| WO2011097643A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EA201270778A1 (ru) | 2010-05-06 | 2013-04-30 | Бристол-Майерс Сквибб Компани | Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119 |
| WO2011149856A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| AU2011282243B2 (en) | 2010-07-19 | 2016-09-22 | Ionis Pharmaceuticals, Inc. | Modulation of nuclear-retained RNA |
| WO2012019106A2 (en) | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| CN102617548A (zh) | 2011-01-31 | 2012-08-01 | 北京赛林泰医药技术有限公司 | 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用 |
| WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
| MY163274A (en) | 2011-02-07 | 2017-08-30 | Biogen Ma Inc | S1p modulating agents |
| EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| US9447075B2 (en) | 2011-08-02 | 2016-09-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as EAAT2 activators |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| US9752142B2 (en) | 2011-08-11 | 2017-09-05 | Ionis Pharmaceuticals, Inc. | Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof |
| EP2751269B1 (en) | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| US9662314B2 (en) | 2011-10-21 | 2017-05-30 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
| GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
| AU2012345557A1 (en) | 2011-11-28 | 2014-06-26 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| WO2013101974A1 (en) | 2011-12-30 | 2013-07-04 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2809322B9 (en) | 2012-01-26 | 2019-10-30 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| ES2697174T3 (es) | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| WO2013130689A1 (en) | 2012-03-01 | 2013-09-06 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EA028382B1 (ru) | 2012-03-23 | 2017-11-30 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| US9199946B2 (en) | 2012-04-03 | 2015-12-01 | Bristol-Myers Squibb Company | Pyrimidinone carboxamide inhibitors of endothelial lipase |
| SG10201704095UA (en) | 2012-04-24 | 2017-06-29 | Vertex Pharma | Dna-pk inhibitors |
| BR112014027244A2 (pt) | 2012-05-15 | 2017-06-27 | Novartis Ag | derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1 |
| AU2013289938A1 (en) | 2012-07-13 | 2015-01-29 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| WO2014059356A2 (en) | 2012-10-12 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| EP4144845B1 (en) | 2012-10-12 | 2024-04-24 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| AU2013334139B2 (en) | 2012-10-25 | 2017-08-03 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| JP6255711B2 (ja) | 2012-11-01 | 2018-01-10 | 株式会社リコー | エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子 |
| US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| WO2014121287A2 (en) | 2013-02-04 | 2014-08-07 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| CA2910508A1 (en) | 2013-05-14 | 2014-11-20 | Song Feng | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
| JP6492071B2 (ja) | 2013-06-25 | 2019-03-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮を処置するための化合物 |
| WO2015017589A1 (en) | 2013-07-31 | 2015-02-05 | Novartis Ag | 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions |
| WO2015024876A2 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| ES2699354T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2 |
| AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
| MX379110B (es) | 2014-03-14 | 2025-03-11 | Raqualia Pharma Inc | Derivados de azaspiro como antagonistas de trpm8. |
| WO2015143185A1 (en) | 2014-03-19 | 2015-09-24 | Amydis Diagnostics | Amyloid targeting agents and methods of using the same |
| JP6236173B2 (ja) | 2014-05-15 | 2017-11-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための化合物 |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3157875A2 (en) | 2014-06-17 | 2017-04-26 | Novozymes A/S | Biological phosphorus removal from wastewater |
| KR102565544B1 (ko) | 2014-06-25 | 2023-08-10 | 에프. 호프만-라 로슈 아게 | 척수성 근위축증을 치료하기 위한 이미다조[1,2-a]피라진-1일-벤즈아마이드 화합물 |
| WO2016070107A1 (en) | 2014-10-31 | 2016-05-06 | The General Hospital Corporation | Potent gamma-secretase modulators |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| HUE043842T2 (hu) | 2014-12-24 | 2019-09-30 | Uniqure Ip Bv | RNAi-indukált huntingtin gén szuppresszió |
| US10676475B2 (en) | 2015-01-16 | 2020-06-09 | The General Hospital Corporation | Compounds for improving mRNA splicing |
| WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
| GB201502567D0 (en) | 2015-02-16 | 2015-04-01 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201506933D0 (en) | 2015-04-23 | 2015-06-10 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP6749343B2 (ja) | 2015-05-20 | 2020-09-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための化合物 |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| CN108289959B (zh) | 2015-11-12 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的组合物 |
| AU2016351919B2 (en) | 2015-11-12 | 2020-11-12 | F. Hoffmann-La Roche Ag | Compounds for treating amyotrophic lateral sclerosis |
| US10383867B2 (en) | 2015-11-28 | 2019-08-20 | Russell Dahl | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| CN116199700A (zh) * | 2016-03-11 | 2023-06-02 | Ac免疫有限公司 | 用于诊断和治疗的双环化合物 |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| JP7044375B2 (ja) | 2016-05-31 | 2022-03-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｐｔｐｎ１１の複素環式阻害剤 |
| KR102494647B1 (ko) | 2016-07-14 | 2023-01-31 | 브리스톨-마이어스 스큅 컴퍼니 | 비시클릭 헤테로아릴 치환된 화합물 |
| US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| EP3606562A4 (en) | 2017-04-03 | 2020-11-11 | Acceleron Pharma Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL AMYOTROPHIA |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| JP7376471B2 (ja) | 2017-06-05 | 2023-11-08 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
| IL272413B (en) | 2017-08-04 | 2022-09-01 | Skyhawk Therapeutics Inc | Methods and compositions for fusion modulation |
| EP3755699A1 (en) | 2018-02-21 | 2020-12-30 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| AU2019240299B2 (en) | 2018-03-21 | 2023-06-22 | D.E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| SMT202400286T1 (it) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics Inc | Composti eterociclici ed eteroarilici per il trattamento della corea di huntington |
| AU2019294482B2 (en) | 2018-06-27 | 2022-09-01 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| JP2022525417A (ja) | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
| JP7649257B2 (ja) | 2019-05-13 | 2025-03-19 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| CN114650822A (zh) | 2019-11-01 | 2022-06-21 | 诺华股份有限公司 | 剪接调节子用于减慢亨廷顿氏病进展的治疗的用途 |
| US20230234942A1 (en) | 2020-04-09 | 2023-07-27 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| IL302839A (en) | 2020-11-12 | 2023-07-01 | Ptc Therapeutics Inc | Novel rna transcript |
| WO2023009816A1 (en) | 2021-07-30 | 2023-02-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
-
2019
- 2019-06-25 AU AU2019294482A patent/AU2019294482B2/en active Active
- 2019-06-25 EP EP19736947.3A patent/EP3814345B8/en active Active
- 2019-06-25 KR KR1020207036998A patent/KR20210038845A/ko not_active Ceased
- 2019-06-25 SG SG11202012869SA patent/SG11202012869SA/en unknown
- 2019-06-25 EA EA202092899A patent/EA202092899A1/ru unknown
- 2019-06-25 BR BR112020026534-9A patent/BR112020026534A2/pt unknown
- 2019-06-25 CA CA3104516A patent/CA3104516A1/en active Pending
- 2019-06-25 JP JP2020572894A patent/JP7515415B2/ja active Active
- 2019-06-25 WO PCT/US2019/038895 patent/WO2020005877A1/en not_active Ceased
- 2019-06-25 CN CN201980050967.1A patent/CN112805280B/zh active Active
- 2019-06-25 MX MX2020014315A patent/MX2020014315A/es unknown
- 2019-06-25 US US17/254,828 patent/US12139499B2/en active Active
-
2020
- 2020-12-23 IL IL279714A patent/IL279714A/en unknown
-
2022
- 2022-07-28 AU AU2022209304A patent/AU2022209304A1/en not_active Abandoned
-
2024
- 2024-04-26 JP JP2024072881A patent/JP2024105367A/ja not_active Abandoned
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009531376A (ja) | 2006-03-28 | 2009-09-03 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | ヒスタミンｈ３受容体活性を有するベンゾチアゾール |
| JP2011507884A (ja) | 2007-12-20 | 2011-03-10 | アボット・ラボラトリーズ | ベンゾチアゾールおよびベンゾオキサゾール誘導体ならびに使用方法 |
| WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
| WO2010024903A1 (en) | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| JP2013040945A (ja) | 2011-08-18 | 2013-02-28 | Korea Institute Of Science And Technology | 退行性脳疾患の予防用または治療用の薬学的組成物及びそのスクリーニング方法 |
| JP2018500302A (ja) | 2014-12-02 | 2018-01-11 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての二環式化合物 |
| WO2016144351A1 (en) | 2015-03-11 | 2016-09-15 | E. I. Du Pont De Nemours And Company | Heterocycle-substituted bicyclic azole pesticides |
| WO2017100726A1 (en) | 2015-12-10 | 2017-06-15 | Ptc Therapeutics, Inc. | Methods for treatng huntington's disease |
| WO2017175068A1 (en) | 2016-04-08 | 2017-10-12 | Mankind Pharma Ltd. | Thiazolopyridine derivatives as gpr119 agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021528466A (ja) | 2021-10-21 |
| EP3814345B1 (en) | 2024-09-25 |
| EP3814345A1 (en) | 2021-05-05 |
| AU2019294482A1 (en) | 2021-01-21 |
| NZ771342A (en) | 2025-06-27 |
| KR20210038845A (ko) | 2021-04-08 |
| SG11202012869SA (en) | 2021-01-28 |
| EP3814345B8 (en) | 2024-10-30 |
| CA3104516A1 (en) | 2020-01-02 |
| MX2020014315A (es) | 2021-05-27 |
| WO2020005877A1 (en) | 2020-01-02 |
| CN112805280B (zh) | 2024-12-06 |
| US20210284660A1 (en) | 2021-09-16 |
| EA202092899A1 (ru) | 2021-05-14 |
| JP2024105367A (ja) | 2024-08-06 |
| AU2019294482B2 (en) | 2022-09-01 |
| CN112805280A (zh) | 2021-05-14 |
| AU2022209304A1 (en) | 2022-08-25 |
| BR112020026534A2 (pt) | 2021-03-23 |
| US12139499B2 (en) | 2024-11-12 |
| IL279714A (en) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7515415B2 (ja) | ハンチントン病を処置するためのヘテロアリール化合物 | |
| US12384789B2 (en) | Compounds for treating Huntington's disease | |
| JP7399870B2 (ja) | ハンチントン病を処置するための化合物 | |
| US11685746B2 (en) | Heteroaryl compounds for treating Huntington's disease | |
| JP7649257B2 (ja) | ハンチントン病を処置するための化合物 | |
| HK40043147B (en) | Heteroaryl compounds for treating huntington's disease | |
| HK40043147A (en) | Heteroaryl compounds for treating huntington's disease | |
| EA045014B1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
| EA041957B1 (ru) | Соединения для лечения болезни гентингтона | |
| EA043655B1 (ru) | Соединения для лечения болезни хантингтона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220613 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220613 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230417 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230919 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240426 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240520 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240603 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240702 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7515415 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |